Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer By Ogkologos - July 15, 2025 713 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... August 14, 2025 Sister Is There To Comfort Her Little Brother As He Battles... September 10, 2019 EMA Recommends Granting a Marketing Authorisation for Azacitidine May 3, 2021 The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... July 16, 2018 Load more HOT NEWS Access to Cancer Medicines and Clinical Trials Show Stark Variations Across... Poziotinib Shows Promising Antitumour Activity in Patients with HER2 Exon 20... Aiming to Prevent New Cancer Cases, ESMO Calls for Increased Minimum... Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC...
